French health authorities established strict new prescription controls for the psychostimulants Xurta and Tentin on larevuedupraticien.fr, according to Larevuedupraticien. The amphetamine-type medications are now classified under narcotics regulations to curb risks of abuse, misuse, and dependence.
Initial prescriptions are strictly limited to specialists in neurology, psychiatry, or pediatrics. Subsequent annual renewals also require these specialists, while any doctor can handle intermediate renewals. Patients must obtain the medications through secure paper prescriptions or digital orders via health insurance tele-services.
Therapies cannot exceed a 28-day duration per prescription. Regulators implemented these measures to manage known risks including cardiovascular, neuropsychiatric, and cerebrovascular side effects. Methylphenidate products remain exempt from this new oversight framework.
Reimbursement Requirements and Patient Assessments
Specialists must complete a specific reimbursement form during the initial prescription. This document verifies that doctors prescribe the drugs strictly within reimbursable therapeutic indications.
Physicians hand the physical justification form directly to the patient alongside the prescription. Reimbursement is impossible without this document.
The evaluation questions target specific patient criteria. larevuedupraticien.fr reported that the questions verify the patient’s age and confirm a strict attention deficit hyperactivity disorder diagnosis. The assessment also checks for prior treatment failure with methylphenidate in children, or childhood symptom presence in adults.
Frequently Asked Questions
Which medical specialists can initiate treatment with Xurta and Tentin?
Treatment initiation is restricted exclusively to specialists in neurology, psychiatry, or pediatrics, according to larevuedupraticien.fr.
What is the maximum duration for a single prescription?
Prescriptions for both psychostimulant medications are strictly limited to a maximum of 28 days.
Are methylphenidate-based medications subject to these new rules?
Specialties based on methylphenidate are not affected by this specific prescription support mechanism.
Related reading